considerations for the new four-month rifapentine-moxifloxacin regimen for drug-susceptible tb
Published 2 years ago • 1.8K plays • Length 1:58:41Download video MP4
Download video MP3
Similar videos
-
59:08
tb 101 series 2024: session 4 - treatment for tb infection
-
2:30
shorter course for tuberculosis treatment | nejm
-
1:16:33
tb 101 series 2023: session 4 - treatment of ltbi
-
23:48
tb 2022 international conference new treatment regimen
-
1:07:34
tb 101 series 2023: session 8: treatment of tb disease
-
17:55
treating latent tb infection (ltbi)
-
28:39
what’s new for tb treatment?
-
20:52
what’s new in the treatment of rifampin resistant tb - francesca conradie, mbbch
-
41:09
2024 tb 101 series: diagnosis and treatment of tb in children
-
1:10:46
2024 tb 101 series: diagnosis of tb disease
-
1:09:06
2024 tb 101 series: session 2 - transmission and pathogenesis
-
0:37
treatment for latent tuberculosis infection
-
1:10:52
2024 tb 101 series: treatment of tb disease
-
11:32
tuberculosis - causes, symptoms, diagnosis, treatment, pathology
-
1:22:54
2024 tb 101 series: monitoring patients during tb therapy
-
13:10
updates in tb preventive therapy guidelines
-
1:00:22
new tb treatment regimens
-
8:58
rifampin vs. rifapentine: a debate over the preferred rifamycin | charles peloquin, pharmd
-
1:19:34
tb 101 series 2023: session 11 - monitoring patients during tb therapy
-
10:48
4-month regimen for tb disease - horne 4-4-2022
-
56:06
tb 101 series 2023: session 10 - case management and treatment adherence
-
1:00:58
updates in pulmonary tuberculosis treatment: progress and looking to the future